NASDAQ:FGEN - Nasdaq - US31572Q8087 - Common Stock - Currency: USD
0.2867
+0 (+0.14%)
The current stock price of FGEN is 0.2867 USD. In the past month the price decreased by -8.98%. In the past year, price decreased by -72.43%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 16.81 | 301.01B | ||
AMGN | AMGEN INC | 13.81 | 147.14B | ||
GILD | GILEAD SCIENCES INC | 22.63 | 130.06B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1646.62 | 122.76B | ||
REGN | REGENERON PHARMACEUTICALS | 12.3 | 61.38B | ||
ARGX | ARGENX SE - ADR | 320.27 | 36.37B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.28B | ||
ONC | BEIGENE LTD-ADR | N/A | 24.70B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.47B | ||
NTRA | NATERA INC | N/A | 19.23B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.60B | ||
BIIB | BIOGEN INC | 7.07 | 17.05B |
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 486 full-time employees. The company went IPO on 2014-11-14. The firm is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. The company also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.
FIBROGEN INC
350 Bay Street, Suite 100 #6009
San Francisco CALIFORNIA 94158 US
CEO: Enrique Conterno
Employees: 486
Company Website: https://www.fibrogen.com/
Investor Relations: https://investor.fibrogen.com
Phone: 14159781200
The current stock price of FGEN is 0.2867 USD. The price increased by 0.14% in the last trading session.
The exchange symbol of FIBROGEN INC is FGEN and it is listed on the Nasdaq exchange.
FGEN stock is listed on the Nasdaq exchange.
8 analysts have analysed FGEN and the average price target is 10.2 USD. This implies a price increase of 3457.73% is expected in the next year compared to the current price of 0.2867. Check the FIBROGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
FIBROGEN INC (FGEN) has a market capitalization of 28.93M USD. This makes FGEN a Nano Cap stock.
FIBROGEN INC (FGEN) currently has 486 employees.
FIBROGEN INC (FGEN) has a resistance level at 0.31. Check the full technical report for a detailed analysis of FGEN support and resistance levels.
The Revenue of FIBROGEN INC (FGEN) is expected to decline by -45.65% in the next year. Check the estimates tab for more information on the FGEN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
FGEN does not pay a dividend.
FIBROGEN INC (FGEN) will report earnings on 2025-05-12, after the market close.
FIBROGEN INC (FGEN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.48).
The outstanding short interest for FIBROGEN INC (FGEN) is 5.31% of its float. Check the ownership tab for more information on the FGEN short interest.
ChartMill assigns a fundamental rating of 1 / 10 to FGEN. FGEN may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months FGEN reported a non-GAAP Earnings per Share(EPS) of -0.48. The EPS increased by 82.86% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -22.18% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to FGEN. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -49.81% and a revenue growth -45.65% for FGEN